Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial

Sarah Ballou, Ted J Kaptchuk, William Hirsch, Judy Nee, Johanna Iturrino, Kathryn T Hall, John M Kelley, Vivian Cheng, Irving Kirsch, Eric Jacobson, Lisa Conboy, Anthony Lembo, Roger B Davis, Sarah Ballou, Ted J Kaptchuk, William Hirsch, Judy Nee, Johanna Iturrino, Kathryn T Hall, John M Kelley, Vivian Cheng, Irving Kirsch, Eric Jacobson, Lisa Conboy, Anthony Lembo, Roger B Davis

Abstract

Background: Placebo medications, by definition, are composed of inactive ingredients that have no physiological effect on symptoms. Nonetheless, administration of placebo in randomized controlled trials (RCTs) and in clinical settings has been demonstrated to have significant impact on many physical and psychological complaints. Until recently, conventional wisdom has suggested that patients must believe that placebo pills actually contain (or, at least, might possibly contain) active medication in order to elicit a response to placebo. However, several recent RCTs, including patients with irritable bowel syndrome (IBS), chronic low back pain, and episodic migraine, have demonstrated that individuals receiving open-label placebo (OLP) can still experience symptomatic improvement and benefit from honestly described placebo treatment.

Methods and design: This paper describes an innovative multidisciplinary trial design (n = 280) that attempts to replicate and expand upon an earlier IBS OLP study. The current study will compare OLP to double-blind placebo (DBP) administration which is made possible by including a nested, double-blind RCT comparing DBP and peppermint oil. The study also examines possible genetic and psychological predictors of OLP and seeks to better understand participants' experiences with OLP and DBP through a series of extensive interviews with a randomly selected subgroup.

Discussion: OLP treatment is a novel strategy for ethically harnessing placebo effects. It has potential to re-frame theories of placebo and to influence how physicians can optimize watch-and-wait strategies for common, subjective symptoms. The current study aims to dramatically expand what we know about OLP by comparing, for the first time, OLP and DBP administration. Adopting a unique, multidisciplinary approach, the study also explores genetic, psychological and experiential dimensions of OLP. The paper ends with an extensive discussion of the "culture" of the trial as well as potential mechanisms of OLP and ethical implications.

Trial registration: ClinicalTrials.gov, identifier: NCT02802241 . Registered on 14 June 2016.

Keywords: Irritable bowel syndrome; Multi-disciplinary models; Open-label placebo; Peppermint oil; Placebo effects; Research methods.

Figures

Fig. 1
Fig. 1
Treatment arms and sample sizes
Fig. 2
Fig. 2
Schedule of enrollment, interventions, and assessments

References

    1. Kaptchuk TJ, Miller FG. Placebo effects in medicine. N Engl J Med. 2015;373(1):8–9. doi: 10.1056/NEJMp1504023.
    1. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet Lond Engl. 2010;375(9715):686–95. doi: 10.1016/S0140-6736(09)61706-2.
    1. Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci. 2015;16(7):403–18. doi: 10.1038/nrn3976.
    1. Tilburt JC, Emanuel EJ, Kaptchuk TJ, Curlin FA, Miller FG. Prescribing “placebo treatments”: results of national survey of US internists and rheumatologists. BMJ. 2008;337:a1938. doi: 10.1136/bmj.a1938.
    1. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455–63. doi: 10.7326/0003-4819-133-6-200009190-00014.
    1. Blease CR, Bishop FL, Kaptchuk TJ. Informed consent and clinical trials: where is the placebo effect? BMJ. 2017;356:j463. doi: 10.1136/bmj.j463.
    1. Raicek JE, Stone BH, Kaptchuk TJ. Placebos in 19th century medicine: a quantitative analysis of the BMJ. BMJ. 2012;345:e8326. doi: 10.1136/bmj.e8326.
    1. Kaptchuk TJ. Placebo studies and ritual theory: a comparative analysis of Navajo, acupuncture and biomedical healing. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1849–58. doi: 10.1098/rstb.2010.0385.
    1. Kaptchuk TJ. Powerful placebo: the dark side of the randomised controlled trial. Lancet Lond Engl. 1998;351(9117):1722–5. doi: 10.1016/S0140-6736(97)10111-8.
    1. Kaptchuk TJ. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med. 1998;72(3):389–433. doi: 10.1353/bhm.1998.0159.
    1. Bok S. The ethics of giving placebos. Sci Am. 1974;231(5):17–23. doi: 10.1038/scientificamerican1174-17.
    1. Meissner K, Höfner L, Fässler M, Linde K. Widespread use of pure and impure placebo interventions by GPs in Germany. Fam Pract. 2012;29(1):79–85. doi: 10.1093/fampra/cmr045.
    1. Fässler M, Meissner K, Schneider A, Linde K. Frequency and circumstances of placebo use in clinical practice—a systematic review of empirical studies. BMC Med. 2010;8:15. doi: 10.1186/1741-7015-8-15.
    1. Kermen R, Hickner J, Brody H, Hasham I. Family physicians believe the placebo effect is therapeutic but often use real drugs as placebos. Fam Med. 2010;42(9):636–42.
    1. Blease C, Colloca L, Kaptchuk TJ. Are open-label placebos ethical? Informed consent and ethical equivocations. Bioethics. 2016;30(6):407–14. doi: 10.1111/bioe.12245.
    1. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PloS One. 2010;5(12):e15591. doi: 10.1371/journal.pone.0015591.
    1. Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016;157(12):2766–72.
    1. Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218):218ra5. doi: 10.1126/scitranslmed.3006175.
    1. Schaefer M, Harke R, Denke C. Open-label placebos improve symptoms in allergic rhinitis: a randomized controlled trial. Psychother Psychosom. 2016;85(6):373–4. doi: 10.1159/000447242.
    1. Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, Fava M. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom. 2012;81(5):312–4. doi: 10.1159/000337053.
    1. Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. Child Care Health Dev. 2008;34(1):104–10. doi: 10.1111/j.1365-2214.2007.00797.x.
    1. Perlis M, Grandner M, Zee J, Bremer E, Whinnery J, Barilla H, et al. Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. Sleep Med. 2015;16(9):1160–8. doi: 10.1016/j.sleep.2015.06.015.
    1. Ader R, Mercurio MG, Walton J, James D, Davis M, Ojha V, et al. Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom Med. 2010;72(2):192–7. doi: 10.1097/PSY.0b013e3181cbd38b.
    1. Schafer SM, Colloca L, Wager TD. Conditioned placebo analgesia persists when subjects know they are receiving a placebo. J Pain Off J Am Pain Soc. 2015;16(5):412–20. doi: 10.1016/j.jpain.2014.12.008.
    1. Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991;101(1):55–65. doi: 10.1016/0016-5085(91)90459-X.
    1. Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988;2(2):101–18. doi: 10.1111/j.1365-2036.1988.tb00677.x.
    1. Wechsler ME, Kelley JM, Boyd IOE, Dutile S, Marigowda G, Kirsch I, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011;365(2):119–26. doi: 10.1056/NEJMoa1103319.
    1. Sorokin I, Schatz A, Welliver C. Placebo medication and sham surgery responses in benign prostatic hyperplasia treatments: implications for clinical trials. Curr Urol Rep. 2015;16(10):73. doi: 10.1007/s11934-015-0544-4.
    1. Freeman EW, Ensrud KE, Larson JC, Guthrie KA, Carpenter JS, Joffe H, et al. Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictors. Psychosom Med. 2015;77(2):167–75. doi: 10.1097/PSY.0000000000000143.
    1. Qu D, Zhang Z, Yu X, Zhao J, Qiu F, Huang J. Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis. Eur J Cancer Care (Engl) 2016;25(6):970–9. doi: 10.1111/ecc.12397.
    1. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336(7651):999–1003. doi: 10.1136/bmj.39524.439618.25.
    1. Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PloS One. 2012;7(10):e48135. doi: 10.1371/journal.pone.0048135.
    1. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta J-K. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008;65(2):220–31. doi: 10.1001/archgenpsychiatry.2007.34.
    1. De La Fuente-Fernández R, Stoessl AJ. The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof. 2002;25(4):387–98. doi: 10.1177/0163278702238052.
    1. Kelley JM, Lembo AJ, Ablon JS, Villanueva JJ, Conboy LA, Levy R, et al. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med. 2009;71(7):789–97. doi: 10.1097/PSY.0b013e3181acee12.
    1. Kaptchuk TJ, Shaw J, Kerr CE, Conboy LA, Kelley JM, Csordas TJ, et al. “Maybe I made up the whole thing”: placebos and patients’ experiences in a randomized controlled trial. Cult Med Psychiatry. 2009;33(3):382–411. doi: 10.1007/s11013-009-9141-7.
    1. Kerr CE, Shaw JR, Conboy LA, Kelley JM, Jacobson E, Kaptchuk TJ. Placebo acupuncture as a form of ritual touch healing: a neurophenomenological model. Conscious Cogn. 2011;20(3):784–91. doi: 10.1016/j.concog.2010.12.009.
    1. Bishop FL, Jacobson EE, Shaw J, Kaptchuk TJ. Participants’ experiences of being debriefed to placebo allocation in a clinical trial. Qual Health Res. 2012;22(8):1138–49. doi: 10.1177/1049732312448544.
    1. Bishop FL, Jacobson EE, Shaw JR, Kaptchuk TJ. Scientific tools, fake treatments, or triggers for psychological healing: how clinical trial participants conceptualise placebos. Soc Sci Med. 2012;74(5):767–74. doi: 10.1016/j.socscimed.2011.11.020.
    1. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109 Suppl 1:S2–26. doi: 10.1038/ajg.2014.187.
    1. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–1407. doi:10.1053/j.gastro.2016.02.031.
    1. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402. doi: 10.1046/j.1365-2036.1997.142318000.x.
    1. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344(21):1594–602. doi: 10.1056/NEJM200105243442106.
    1. Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med. 2015;21(5):285–94. doi: 10.1016/j.molmed.2015.02.009.
    1. Schafer SM, Colloca L, Wager TD. Placebo-induced decreases in the neurologic pain signature do not always correspond with pain relief. In: Organization of Human Brain Mapping; June 14-18, 2015; Honolulu, Hawaii, USA. 14-18; Abstract #4272 6.
    1. Kirsch I. Response expectancy as a determinant of experience and behavior. Am Psychol. 1985;40(11):1189–202. doi: 10.1037/0003-066X.40.11.1189.
    1. Albring A, Wendt L, Benson S, Nissen S, Yavuz Z, Engler H, et al. Preserving learned immunosuppressive placebo response: perspectives for clinical application. Clin Pharmacol Ther. 2014;96(2):247–55. doi: 10.1038/clpt.2014.75.
    1. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004;130(2):324–40. doi: 10.1037/0033-2909.130.2.324.
    1. Geers AL, Miller FG. Understanding and translating the knowledge about placebo effects: the contribution of psychology. Curr Opin Psychiatry. 2014;27(5):326–31. doi: 10.1097/YCO.0000000000000082.
    1. Ritter W, Sussman E, Deacon D, Cowan N, Vaughan HG. Two cognitive systems simultaneously prepared for opposite events. Psychophysiology. 1999;36(6):835–8. doi: 10.1111/1469-8986.3660835.
    1. Bubic A, von Cramon DY, Schubotz RI. Prediction, cognition and the brain. Front Hum Neurosci. 2010;4:25.
    1. Jensen KB, Kaptchuk TJ, Kirsch I, Raicek J, Lindstrom KM, Berna C, et al. Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci U S A. 2012;109(39):15959–64. doi: 10.1073/pnas.1202056109.
    1. Jensen KB, Kaptchuk TJ, Chen X, Kirsch I, Ingvar M, Gollub RL, et al. A Neural mechanism for nonconscious activation of conditioned placebo and nocebo responses. Cereb Cortex N Y N 1991. 2015;25(10):3903–10.
    1. Jensen K, Kirsch I, Odmalm S, Kaptchuk TJ, Ingvar M. Classical conditioning of analgesic and hyperalgesic pain responses without conscious awareness. Proc Natl Acad Sci U S A. 2015;112(25):7863–7. doi: 10.1073/pnas.1504567112.
    1. Eaves ER, Nichter M, Ritenbaugh C. Ways of hoping: navigating the paradox of hope and despair in chronic pain. Cult Med Psychiatry. 2016;40(1):35–58. doi: 10.1007/s11013-015-9465-4.
    1. Hsu C, Sherman KJ, Eaves ER, Turner JA, Cherkin DC, Cromp D, et al. New perspectives on patient expectations of treatment outcomes: results from qualitative interviews with patients seeking complementary and alternative medicine treatments for chronic low back pain. BMC Complement Altern Med. 2014;14:276. doi: 10.1186/1472-6882-14-276.
    1. Lopez SJ, Snyder CR, Pedrotti J. Positive psychological assessment: a handbook of models and measures. Washington: American Psychological Association; 2003. Hope: many definitions, many measures; pp. 91–107.
    1. Averill J, Sundarajan L. Hope as rhetoric: cultural narratives of wishing and coping. In: Eliott J, editor. Interdisciplinary perspectives on hope. New York: Nova; 2005. pp. 127–59.
    1. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry. 2010;67(8):857–65. doi: 10.1001/archgenpsychiatry.2010.88.
    1. Bergmann JF, Chassany O, Gandiol J, Deblois P, Kanis JA, Segrestaa JM, et al. A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain. Clin Trials Metaanal. 1994;29(1):41–7.
    1. Fiorillo CD, Tobler PN, Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science. 2003;299(5614):1898–902. doi: 10.1126/science.1077349.
    1. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med. 2002;136(11):817–25. doi: 10.7326/0003-4819-136-11-200206040-00011.
    1. Clark A. Surfing uncertainty: prediction, action and the embodied mind. New York: Oxford University Press; 2016.
    1. Kirsch I. Response expectancy: An introduction. In: Kirsch I, editor. How expectancies shape experience. Washington: American Psychological Association; 1999. pp. 3–13.
    1. Dennett D. Consciousness Explained. Penguin: London; 1993.
    1. Clark A. Embodied prediction. In: Metzinger T, editor. Windt JM Open Mind 7(1) Frankfurt am Main: MIND Group; 2015.
    1. Costa VD, Tran VL, Turchi J, Averbeck BB. Dopamine modulates novelty seeking behavior during decision making. Behav Neurosci. 2014;128(5):556–66. doi: 10.1037/a0037128.
    1. Guitart-Masip M, Bunzeck N, Stephan KE, Dolan RJ, Düzel E. Contextual novelty changes reward representations in the striatum. J Neurosci Off J Soc Neurosci. 2010;30(5):1721–6. doi: 10.1523/JNEUROSCI.5331-09.2010.
    1. Winnicott DW. Through paediatrics to psycho-analysis: collected papers. 1st Brunner/Mazel ed. New York: Brunner/Mazel; 1992. p. 50.
    1. Sech SM, Montoya JD, Bernier PA, Barnboym E, Brown S, Gregory A, et al. The so-called “placebo effect” in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology. 1998;51(2):242–50. doi: 10.1016/S0090-4295(97)00609-2.
    1. Goldenholz DM, Moss R, Scott J, Auh S, Theodore WH. Confusing placebo effect with natural history in epilepsy: a big data approach. Ann Neurol. 2015;78(3):329–36. doi: 10.1002/ana.24470.
    1. Hull SC, Colloca L, Avins A, Gordon NP, Somkin CP, Kaptchuk TJ, et al. Patients’ attitudes about the use of placebo treatments: telephone survey. BMJ. 2013;347:f3757. doi: 10.1136/bmj.f3757.
    1. Bishop FL, Aizlewood L, Adams AEM. When and why placebo-prescribing is acceptable and unacceptable: a focus group study of patients’ views. PLoS One. 2014;9(7):e101822. doi: 10.1371/journal.pone.0101822.
    1. Barnhill A. Clinical use of placebos: still the physician’s prerogative? Hastings Cent Rep. 2012;42(3):29–37. doi: 10.1002/hast.33.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren